Experimental group:Anlotinib

5 trials

Sponsors

Department of Thoracic Surgery, Medical Center of Amry Medical University, Yantai Yuhuangding Hospital, Sun Yat-Sen University Cancer Center, The Children’s Hospital, Zhejiang University School of Medicine, Sun Yat-sen University Cancer Center

Conditions

Esophageal carcinomaMalignant brain stem gliomaSalivary gland carcinomasarcomathyroid cancer

Phase 1

Pharmacokinetic study of anlotinib hydrochloride capsules in the treatment of relapsed or refractory pediatric sarcoma

Active, not recruitingChiCTR2300068691

The Children’s Hospital, Zhejiang University School of Medicinesarcoma

Start: 2023-03-01Updated: 2023-05-22

Phase 2

Single-center, single-arm phase II clinical trial of Anlotinib for the treatment of recurrent inoperable or distant metastases of salivary gland carcinoma of head and neck

RecruitingChiCTR2100047475

Sun Yat-Sen University Cancer CenterSalivary gland carcinoma

Start: 2020-05-18Updated: 2022-02-21

Efficacy and safety of antirotinib combined with radiotherapy in the treatment of newly diagnosed malignant brain stem glioma in children

RecruitingChiCTR2300077363

Sun Yat-sen University Cancer CenterMalignant brain stem glioma

Start: 2023-11-20Updated: 2024-10-15

Phase 4

Safety and efficiency of anti-angiogenesis combine with neoadjuvant chemo-radiotherapy in local advanced esophageal squamous cell carcinoma patients followed by esophagectomy

Active, not recruitingChiCTR2000031228

Department of Thoracic Surgery, Medical Center of Amry Medical UniversityEsophageal carcinoma

Start: 2020-04-01Updated: 2020-03-30

Efficacy and safety of anlotinib hydrochloride capsules for targeted therapy in patients with high-risk differentiated thyroid cancer: a single-arm phase II clinical trial

RecruitingChiCTR2100045548

Yantai Yuhuangding Hospitalthyroid cancer

Start: 2021-04-15Updated: 2021-11-29